Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.…
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a…
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant…
Protolabs Supports MIT Industrial Performance Center Research Fellows to Accelerate U.S. Medical and Aerospace Manufacturing Innovation Protolabs the world’s leading provider of digital manufacturing services, today announced a grant to support research fellows at the MIT Industrial Performance Center as…
Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests,announced the enrollment of the first patient in its DIRECT-AI registry…
H.B. Fuller Announces AMS Shareholders Approve Proposed Acquisition H.B. Fuller Company the world’s largest pureplay adhesives company, today announced that shareholders of Advanced Medical Solutions Group plc (“AMS”) (LSE:AMS) approved H.B. Fuller’s proposed acquisition of AMS at specially convened meetings…
Applied BioCode Reports Record Financial Results for the First Half of 2026; Revenue Increases 81% Year Over Year, Driven by Strong U.S. Molecular Diagnostics Growth Applied BioCode, Inc., a leader in high-throughput multiplex molecular diagnostics, announced financial results for the…
Silvec Announces EPA Registration for its Novel Therapy Delivery Technology Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental…
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, announced a collaboration and licensing agreement with Shenzhen CrystalO…
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The…
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights Evommune, Inc. a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026,…
Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, announced that it has received a Catalyze R61 award from the National…